E22 General Considerations for Patient Preference Studies; International Council for Harmonisation; Draft Guidance for Industry; Availability
Published Date: 2/6/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers understand how to include patient preferences in their studies. This new guidance will shape how drugs get developed and approved by making sure patients’ voices count. If you’re in the drug biz, get your comments in by April 7, 2026, or risk missing out on influencing the final rules!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Draft guidance on patient preferences
The FDA released a draft guidance called “E22 General Considerations for Patient Preference Studies” that explains general principles for the use, design, conduct, analysis, and submission of patient preference studies to inform drug development, regulatory submissions, drug approvals, and maintenance of approvals. The ICH Assembly endorsed the draft in November 2025 and the FDA is accepting public comments through April 7, 2026.
Public comment deadline April 7, 2026
Stakeholders who want the FDA to consider their views must submit comments on the draft guidance by April 7, 2026 to ensure the Agency considers those comments before it begins work on the final guidance. Comments can be submitted electronically at https://www.regulations.gov (Docket No. FDA-2026-D-0207) or as written/paper submissions following FDA instructions.
No Paperwork Reduction Act burden
The FDA tentatively concludes that the draft guidance contains no collection of information, so clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required. This means the draft guidance, as written, does not create new information-collection paperwork obligations subject to OMB review.
Guidance is nonbinding and flexible
The FDA states that this draft guidance does not establish legally enforceable responsibilities and represents the Agency's current thinking; sponsors may use alternative approaches if they satisfy applicable statutes and regulations. The final guidance will be reformatted to FDA style and the Agency will consider comments (including on costs or cost savings) as it develops the final version.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
Previous / Next Documents
Previous: 2026-02323, Submission for Office of Management and Budget Review; ACF Performance Progress Report, ACF-OGM-SF-PPR-B
The Administration for Children and Families wants to keep using their Performance Progress Report form for three more years but with fewer questions to make it easier for grantees to fill out. This change affects state, tribal, and local groups who get grants and helps make sure projects stay on track without extra hassle. Comments on these updates are open until March 9, 2026.
Next: 2026-02327, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of filings from energy companies like Arizona Public Service and Duke Energy about changes in their status, refunds, and new agreements. These updates could affect electric rates and services soon, with important comment deadlines mostly in February 2026. If you’re involved in energy or just curious, now’s the time to check out these changes and speak up before the deadlines!